Cargando…

Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison

PURPOSE: Assess the individual and combined diagnostic value of amyloid-PET and tau-PET in a memory clinic population. METHODS: Clinical reports of 136 patients were randomly assigned to two diagnostic pathways: AMY-TAU, amyloid-PET is presented before tau-PET; and TAU-AMY, tau-PET is presented befo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Altomare, Daniele, Caprioglio, Camilla, Assal, Frédéric, Allali, Gilles, Mendes, Aline, Ribaldi, Federica, Ceyzeriat, Kelly, Martins, Marta, Tomczyk, Szymon, Stampacchia, Sara, Dodich, Alessandra, Boccardi, Marina, Chicherio, Christian, Frisoni, Giovanni B., Garibotto, Valentina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175315/ https://www.ncbi.nlm.nih.gov/pubmed/33638661 http://dx.doi.org/10.1007/s00259-021-05246-x

Ejemplares similares

The Biological Substrate of the Motoric Cognitive Risk Syndrome: A Pilot Study Using Amyloid-/Tau-PET and MR Imaging
por: Bommarito, Giulia, et al.
Publicado: (2022)

The Clinical Use of Alzheimer’s Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer’s Disease Consortium Survey
por: Caprioglio, Camilla, et al.
Publicado: (2022)

Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Chiotis, Konstantinos, et al.
Publicado: (2021)

The taxonomy of subjective cognitive decline: proposal and first clinical evidence from the Geneva memory clinic cohort
por: Ribaldi, Federica, et al.
Publicado: (2023)

Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives
por: Cotta Ramusino, Matteo, et al.
Publicado: (2021)

Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Bischof, Gérard N, et al.
Publicado: (2021)

Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design
por: Ribaldi, Federica, et al.
Publicado: (2021)

Prognostic value of imaging-based ATN profiles in a memory clinic cohort
por: Peretti, Débora E., et al.
Publicado: (2023)

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Leuzy, A., et al.
Publicado: (2021)

Clinical validity of increased cortical uptake of [(18)F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
por: Wolters, E. E., et al.
Publicado: (2021)

Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment
por: Mundada, Nidhi S., et al.
Publicado: (2023)

The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
por: Ashton, N. J., et al.
Publicado: (2021)

Predicting amyloid PET and tau PET stages with plasma biomarkers
por: Jack, Clifford R, et al.
Publicado: (2023)

A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
por: Coomans, Emma M., et al.
Publicado: (2023)

Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic
por: Altomare, Daniele, et al.
Publicado: (2023)

Head injury is associated with tau deposition on PET in MCI and AD patients
por: Risacher, Shannon L., et al.
Publicado: (2021)

Topographical Heterogeneity of Alzheimer’s Disease Based on MR Imaging, Tau PET, and Amyloid PET
por: Jeon, Seun, et al.
Publicado: (2019)

FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels
por: Rubinski, Anna, et al.
Publicado: (2020)

Unsupervised [(18)F]Flortaucipir cutoffs for tau positivity and staging in Alzheimer’s disease
por: Quattrini, Giulia, et al.
Publicado: (2023)

Mapping the association between tau-PET and Aβ-amyloid-PET using deep learning
por: Ruwanpathirana, Gihan P., et al.
Publicado: (2022)

Amyloid- and tau-PET imaging in a familial prion kindred
por: Jones, David T., et al.
Publicado: (2018)

Amyloid duration is associated with preclinical cognitive decline and tau PET
por: Koscik, Rebecca L., et al.
Publicado: (2020)

Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia
por: Walker, Zuzana, et al.
Publicado: (2018)

Clinical Applications of FDG PET and PET/CT in Head and Neck Cancer
por: Al-Ibraheem, Akram, et al.
Publicado: (2009)

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
por: Groot, Colin, et al.
Publicado: (2022)

Comprehensive characterization of elevated tau PET signal in the absence of amyloid-beta
por: Weigand, Alexandra J, et al.
Publicado: (2022)

Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition
por: Vemuri, Prashanthi, et al.
Publicado: (2016)

Is tau in the absence of amyloid on the Alzheimer’s continuum?: A study of discordant PET positivity
por: Weigand, Alexandra J, et al.
Publicado: (2019)

Correction to: Comprehensive characterization of elevated tau PET signal in the absence of amyloid-beta
Publicado: (2023)

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
por: Shen, Xue-Ning, et al.
Publicado: (2021)

PET amyloid in normal aging: direct comparison of visual and automatic processing methods
por: Haller, Sven, et al.
Publicado: (2020)

Analysis of Psychological Symptoms Following Disclosure of Amyloid–Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline
por: Caprioglio, Camilla, et al.
Publicado: (2023)

Amyloid and tau PET in cerebral amyloid angiopathy-related inflammation two case reports and literature review
por: Yang, Jhih-Yong, et al.
Publicado: (2023)

Head-to-Head Comparison of [(68) Ga]Ga-FAPI-46-PET/CT and [(18)F]F-FDG-PET/CT for Radiotherapy Planning in Head and Neck Cancer
por: Wegen, Simone, et al.
Publicado: (2022)

Amyloid and Tau Induce Cell Death Independently of TSPO Polymerization and Density Changes
por: Tournier, Benjamin B., et al.
Publicado: (2021)

A Survey of FDG- and Amyloid-PET Imaging in Dementia and GRADE Analysis
por: Daniela, Perani, et al.
Publicado: (2014)

Detection of distant metastases and distant second primary cancers in head and neck squamous cell carcinoma: comparison of [(18)F]FDG PET/MRI and [(18)F]FDG PET/CT
por: Katirtzidou, Eirini, et al.
Publicado: (2022)

White Matter Hyperintensity Volume and Amyloid-PET Synergistically Impact Memory Independent of Tau-PET in Older Adults Without Dementia
por: Edwards, Lauren, et al.
Publicado: (2023)

Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury
por: Mitsis, E M, et al.
Publicado: (2014)

PET/MRI in head and neck cancer: initial experience
por: Platzek, Ivan, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_r8nib59gf6hmm94jbmdpo53dv0